Literature DB >> 3626612

Juvenile monosomy 7 syndrome: evidence that the disease originates in a pluripotent hemopoietic stem cell.

D E Hogge, K M Shannon, D K Kalousek, S Schonberg, V Schaffner, S Zoger, C J Eaves, A C Eaves.   

Abstract

The present study was undertaken to investigate the hemopoietic cell from which malignant change evolves in juvenile dyshemopoiesis with monosomy 7. Two male patients, aged 18 and 5 months, were studied using progenitor assays combined with cytogenetics. Both had hepatosplenomegaly, cytopenias and a cellular marrow. The karyotype in direct marrow was 45,XY-7/47,XY,+8/46,XY in patient 1 and 45,XY,-7/46,XY in patient 2. Patient 1 received chemotherapy but developed acute nonlymphocytic leukemia after 17 months and died 20 months after diagnosis. During this time marrow metaphases with 45,XY,-7 increased to 100% (25/25). Patient 2 received an allogeneic marrow transplant 4 months after diagnosis which did not engraft. In both patients progenitors of both small (CFU-E) and large (BFU-E) erythroid colonies were present at normal frequencies. However, the colonies produced were small and poorly hemoglobinized with some erythropoietin-independent maturation. Progenitors of large granulocyte/macrophage colonies (CFU-GM) were present at an elevated frequency in the marrow of patient 1 and in the blood all progenitor classes were markedly increased. Cytogenetic analysis of colonies from this patient showed BFU-E to be 45,XY,-7 or 47,XY,+8 and CFU-GM to be 45,XY,-7 or 47,XY,+8 or 46,XY. In patient 2, most BFU-E were 45,XY,-7, although a few were 46,XY. These data indicate that malignant change in this disease involves hemopoietic stem cells capable of erythroid and in at least some cases, myeloid differentiation.

Entities:  

Mesh:

Year:  1987        PMID: 3626612     DOI: 10.1016/0145-2126(87)90006-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation.

Authors:  Hiroyuki Fujisaki; Kenji Takai; Sawada Akihisa; Sadao Tokimasa; Yoshiko Matsuda; Hideaki Ohta; Yuko Osugi; Ji Yoo Kim; Gaku Hosoi; Masahiro Sako; Junichi Hara
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

Review 3.  Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).

Authors:  Kelly Mitchell; Ulrich Steidl
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 6.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.